Shamburg News · 8-K filed Nov 10, 2026, 4:12 PM EST

Alto Neuroscience Reports Q3 2026 Net Loss of $25.1 Million; ALTO-207 Trials on Track

ANRO · Alto Neuroscience, Inc.

  • Earnings
  • Financial statements
  • Materiality: high

Alto Neuroscience, Inc. reported financial results for the quarter ended September 30, 2026, including a net loss of $25.1 million, or $0.54 per share, compared with a net loss of $14.2 million, or $0.52 per share, a year earlier. Research and development expenses were $18.2 million and general and administrative expenses were $9.1 million for the quarter. Cash, cash equivalents, and restricted cash were approximately $319.8 million as of September 30, 2026, which the company expects to fund planned operations through 2030.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001999480-26-000030.

Written from the filing by Shamburg Markets. Figures are as reported by the company.